Blood samples for PK

BIOLOGICAL4 trials

Sponsors

Full-Life Technologies GmbH, Haukeland University Hospital, Centre Hospitalier Universitaire de Saint Etienne, Poitiers University Hospital

Conditions

AbemaciclibAbemaciclib-related DiarrheaBreast CancerFibrinogen Deficiency in Complex Cardiac SurgeryMetastatic Castration-resistant Prostate CancerRelapsing Remitting Multiple Sclerosis

Phase 1

Study With [225Ac]Ac-FL-020 in mCRPC Participants

RecruitingNCT06492122

Full-Life Technologies GmbHMetastatic Castration-resistant Prostate Cancer

Start: 2024-08-30End: 2026-12-01Target: 50Updated: 2026-01-29

Phase 4

Pharmacokinetic Model of Abemaciclib: Correlation With Severe Diarrhea as the Primary Toxicity Endpoint in Patients With Localized Hormone Receptor-positive Breast Cancer

Not yet recruitingNCT07490509

Poitiers University HospitalAbemaciclib, Abemaciclib-related Diarrhea, Breast Cancer

Start: 2026-04-01End: 2029-04-01Target: 235Updated: 2026-04-01

Unknown Phase

Rituximab and Ocrelizumab in Serum With Multiple Sclerosis

RecruitingNCT06663111

Haukeland University HospitalRelapsing Remitting Multiple Sclerosis

Start: 2021-03-15End: 2027-12-31Target: 60Updated: 2024-10-29

Individualized Dose of Fibrinogen Following Cardiopulmonary Bypass

Not yet recruitingNCT07425600

Centre Hospitalier Universitaire de Saint EtienneFibrinogen Deficiency in Complex Cardiac Surgery

Start: 2026-03-01End: 2028-09-07Target: 150Updated: 2026-02-23

Related Papers

A first-in-human, phase 1 dose escalation and expansion study evaluating the safety, tolerability, and anti-tumor activity of [225Ac]Ac-FL-020, an anti-PSMA radioconjugate, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2025-05-28